The epidermal growth factor receptor (EGFR) gene mutations are found in ~10% of lung adenocarcinomas in Caucasian population [3], but in 30% ~ 50% of Asian population [7, 8], which define a substantial population that can benefit from the use of EGFR tyrosine kinase inhibitors (TKIs). This evidence concerns the gene EGFR and lung adenocarcinoma.